An optimized workflow for improved gene expression profiling for formalin-fixed, paraffin-embedded tumor samples

Journal of Clinical Bioinformatics

Volumn 3, Issue 1, 2013, Pages

  Thomas, Marlene ^a   Poignée Heger, Manuela ^a   Weisser, Martin ^a   Wessner, Stephanie ^a   Belousov, Anton ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Biomarker; Breast cancer; Gene; HER2; Microarray

Indexed keywords

EID: 84896386927     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-3-10     Document Type: Article

References (37)

1. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996, 14:457-460.
2. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999, 64:71-78. 10.1101/sqb.1999.64.71, 11232339.
3. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001, 195:41-52. 10.1002/path.889, 11568890.
4. Rew DA. DNA microarray technology in cancer research. Eur J Surg Oncol 2001, 27:504-508. 10.1053/ejso.2001.1116, 11504524.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclass with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
8. Bosman FT, Yan P, Tejpar S, Fiocca R, Van Cutsem E, Kennedy RD, Dietrich D, Roth A. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 2009, 15:5528-5533. 10.1158/1078-0432.CCR-09-0741, 19690194.
9. Linton KM, Hey Y, Saunders E, Jeziorska M, Denton J, Wilson CL, Swindell R, Dibben S, Miller CJ, Pepper SD, Radford JA, Freemont JA. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer 2008, 98:1403-1414. 10.1038/sj.bjc.6604316, 2361698, 18382428.
10. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One 2007, 2:e1261. 10.1371/journal.pone.0001261, 2092395, 18060057.
11. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive - gene expression in paraffin-embedded tissue. J Pathol 2001, 195:66-71. 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F, 11568892.
12. Chung J-Y, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, Song YK, Libutti SK, Hewitt SM. Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 2008, 56:1033-1042. 10.1369/jhc.2008.951863, 2569903, 18711211.
13. Oberli A, Popovici V, Delorenzi M, Baltzer A, Antonov J, Matthey S, Aebi S, Altermatt HJ, Jaggi R. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genomics 2008, 1:9. 10.1186/1755-8794-1-9, 2359756, 18423048.
14. Tanney A, Kennedy RD. Developing mRNA-based biomarkers from formalin-fixed paraffin-embedded tissue. Personalized Medicine 2010, 7:205-211.
15. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004, 165:1799-1807. 10.1016/S0002-9440(10)63435-9, 1618650, 15509548.
16. Scicchitano MS, Dalmas DA, Bertiaux MA, Anderson SM, Turner LR, Thomas RA, Mirable R, Boyce RW. Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples. J Histochem Cytochem 2006, 54:1229-1237. 10.1369/jhc.6A6999.2006, 16864893.
17. Frank M, Döring C, Metzler D, Eckerle S, Hansmann ML. Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: a comparison to snap-frozen material using oligonucleotide microarrays. Virchows Arch 2007, 450:699-711. 10.1007/s00428-007-0412-9, 17479285.
18. Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, Werner M. A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin embedded colorectal cancer resection specimens. J Mol Med (Berl) 2009, 87:211-224.
19. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K, Matulonis U, Quackenbush J, Fan JB. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 2009, 4:e8162. 10.1371/journal.pone.0008162, 2780295, 19997620.
20. Fedorowicz G, Guerrero S, Wu TD, Modrusan Z. Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics 2009, 2:23. 10.1186/1755-8794-2-23, 2694827, 19426511.
21. Linton KM, Hey Y, Dibben S, Miller CJ, Freemont AJ, Radford JA, Pepper S. Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques 2009, 47:587-596. 10.2144/000113169, 19594443.
22. Williams PM, Li R, Johnson NA, Wright G, Heath JD, Gascoyne RD. A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn 2010, 12:680-686. 10.2353/jmoldx.2010.090164, 2928433, 20688907.
23. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
24. Refseq and UniGene http://www.ncbi.nlm.nih.gov/guide/genes-expression/, Refseq and UniGene.
25. EMBL http://www.ebi.ac.uk/embl/index.html.
26. Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH, Huang CY. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007, 8:140. 10.1186/1471-2164-8-140, 1894975, 17540040.
27. Jolliffe IT. Principal component analysis 2002, N.Y.: Springer, 2.
28. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257. 10.1056/NEJMoa022289, 3584639, 12867608.
29. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511. 10.1038/35000501, 10676951.
30. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947. 10.1056/NEJMoa012914, 12075054.
31. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009, 15:502-510. 10.1158/1078-0432.CCR-08-1916, 19147755.
32. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP working group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genet Med 2009, 11:66-73. 2743614, 19125125, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
33. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384. 10.1016/S0140-6736(09)61964-4, 20113825.
34. Bianchini G, Prat A, Pickl M, Belousov A, Koehler A, Semiglazov V, Eiermann W, Tjulandin S, Biakhov M, Lluch A, Zambetti M, Vazquez Mazon FJ, Baselga J, Gianni L. Response to neoadjuvant trastuzumab and chemotherapy in ER + and ER- HER2-positive breast cancers: Gene expression analysis. J Clin Oncol 2011, 29(Suppl):529.
35. Gomez Pardo P, Prat A, Bianchini G, Pickl M, Belousov A, Koehler A, Semiglazov V, Eiermann W, Tjulandin S, Biakhov M, Lluch A, Zambetti M, Vazquez-Mazon F, Gianni L, Baselga J. PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. J Clin Oncol 2011, 29(Suppl):554.
36. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008, 132:1929-1935.
37. Chung JY, Hewitt SM. An optimized RNA extraction method from archival formalin-fixed paraffin-embedded tissue. Methods Mol Biol 2010, 611:19-27. 10.1007/978-1-60327-345-9_2, 19960319.